Initial $100 million term loan to propel market share growth in the U.S. SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced it has entered into a senior secured term loan facility of up to $250 million with an affiliate of RA Capital Management (RA Capital), the company's largest shareholder, and an affiliate of OMERS Life Sciences as lenders. ARS Pharma has borrowed an initial $100 million, which will be used primarily to accelerate nef

neffy 1 mg and 2 mg doses approved by Japanese regulators neffy offers a new delivery method for epinephrine in Japan for adults and children (>15 kg) living with severe allergic reactions Alfresa Holdings, which owns the rights to market neffy in Japan, expects availability in Q4 2025 SAN DIEGO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that the Pharmaceuticals and Medical Devices Agency (PMDA), the Japanese authority responsible for the scientific review of

– Accomplished biopharma executive and entrepreneur brings a 25-year track record of upscaling valuable companies and realizing the potential of their innovations – SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced the appointment of Laura Shawver, Ph.D., as Chair of its Board of Directors. "We are honored to welcome Dr. Shawver to our Board. Laura's outstanding track record of driving strategic growth and developing innovative therapies comes at a pivotal time as we scale to advance our pipeline and expand the impact of our next-generation

Findings accepted for publication in the official journal of the American College of Allergy, Asthma and Immunology About 9 out of every 10 patients experiencing anaphylaxis were effectively treated with a single dose of neffy Results suggest real-world effectiveness of neffy is consistent with that historically reported for epinephrine injection SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a commercial stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today shares real-world evidence evaluating the clinical performance

SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced that Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer will participate in presentations at the Cantor Global Healthcare Conference and the Stifel Immunology and Inflammation Summit in September. Details outlined below. Cantor Global Healthcare Conference Presentation (Fireside Chat): Wednesday, September 3, 2025Time: 3:55 p.m. ET Location: New YorkA live webcast of the presen

$15.7 million in revenue, including $12.8 million in neffy U.S. net product revenue in second quarter of 2025 Growth for neffy in the U.S. driven by increased payor access with additional near-term growth anticipated from national direct-to-consumer (DTC) campaign and pediatric co-promote partnership 93% commercial coverage achieved with streamlined prior authorization process with approval rates at the pharmacy benefit manager (PBM) comparable to overall epinephrine market EURneffy® approved in the United Kingdom and launched in Germany, now representing a global footprint with this first and only needle-free epinephrine treatment Conference call to be held today, August 13, 2025, at 5:

SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, August 13, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its second quarter 2025 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company's website

EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions ALK-Abelló A/S, which owns the rights to market EURneffy in the U.K., expects availability in late Q3 2025 U.K. is the largest market outside the U.S. for adrenaline (epinephrine) auto-injector sales SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that the United Kingdom (U.K.) Medicines and Healthcare produ

SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced that Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer, will participate in presentations at the William Blair 45th Annual Growth Stock Conference and 2025 Jefferies Global Healthcare Conference in June. Details outlined below. William Blair 45th Annual Growth Stock ConferencePresentation: Tuesday, June 3, 2025Time: 11:20 a.m. CTLocation: ChicagoA live webcast of the presentati

$7.8 million in total neffy U.S. net product revenue in first quarter of 2025 neffy 1 mg available nationwide for children aged four and older and co-promotion agreement with ALK-Abelló Inc. increases neffy promotional reach to nearly 20,000 healthcare providers, including key pediatricians More than 5,000 physicians have prescribed neffy to date, reinforcing the demand for a safe, effective, needle-free treatment for severe allergic reactions including anaphylaxis Conference call to be held today, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering

Roth Capital initiated coverage of ARS Pharmaceuticals with a rating of Buy and set a new price target of $40.00

Scotiabank initiated coverage of ARS Pharmaceuticals with a rating of Sector Outperform and set a new price target of $30.00

Oppenheimer initiated coverage of ARS Pharmaceuticals with a rating of Outperform and set a new price target of $40.00

Cantor Fitzgerald initiated coverage of ARS Pharmaceuticals with a rating of Overweight

Raymond James upgraded ARS Pharmaceuticals from Outperform to Strong Buy and set a new price target of $22.00 from $18.00 previously

Leerink Partners reiterated coverage of ARS Pharmaceuticals with a rating of Outperform and set a new price target of $20.00 from $19.00 previously

Raymond James initiated coverage of ARS Pharmaceuticals with a rating of Outperform and set a new price target of $18.00

Leerink Partners upgraded ARS Pharmaceuticals from Market Perform to Outperform and set a new price target of $18.00 from $6.00 previously

William Blair upgraded ARS Pharmaceuticals from Mkt Perform to Outperform

William Blair downgraded ARS Pharmaceuticals from Outperform to Mkt Perform

4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

– Accomplished biopharma executive and entrepreneur brings a 25-year track record of upscaling valuable companies and realizing the potential of their innovations – SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced the appointment of Laura Shawver, Ph.D., as Chair of its Board of Directors. "We are honored to welcome Dr. Shawver to our Board. Laura's outstanding track record of driving strategic growth and developing innovative therapies comes at a pivotal time as we scale to advance our pipeline and expand the impact of our next-generation

Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that Express Scripts, the pharmacy benefits business of Evernorth Health Services, has added neffy® (epinephrine nasal spray) to its Commercial national formularies. This decision makes neffy broadly available to millions of their commercially insured

$15.7 million in revenue, including $12.8 million in neffy U.S. net product revenue in second quarter of 2025 Growth for neffy in the U.S. driven by increased payor access with additional near-term growth anticipated from national direct-to-consumer (DTC) campaign and pediatric co-promote partnership 93% commercial coverage achieved with streamlined prior authorization process with approval rates at the pharmacy benefit manager (PBM) comparable to overall epinephrine market EURneffy® approved in the United Kingdom and launched in Germany, now representing a global footprint with this first and only needle-free epinephrine treatment Conference call to be held today, August 13, 2025, at 5:

SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, August 13, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its second quarter 2025 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company's website

$7.8 million in total neffy U.S. net product revenue in first quarter of 2025 neffy 1 mg available nationwide for children aged four and older and co-promotion agreement with ALK-Abelló Inc. increases neffy promotional reach to nearly 20,000 healthcare providers, including key pediatricians More than 5,000 physicians have prescribed neffy to date, reinforcing the demand for a safe, effective, needle-free treatment for severe allergic reactions including anaphylaxis Conference call to be held today, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering

SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its first quarter 2025 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company's website. A repla

$7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing 15 kilograms to < 30 kilograms (33 lbs. to < 66 lbs.), expanding the reach of neffy to approximately 2 million younger, school-aged children at risk of a severe allergic reaction $314.0 million in cash, cash equivalents, and short-term investments at year-end 2024, supporting an increased investment in commercialization in 2025 while maintaining an operating runway of at least three years Company to host conference call today, March 20, 2025 at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, March

Company to Host Conference Call on March 20 at 8:30 a.m. ET SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Thursday, March 20, 2025, at 8:30 a.m. ET to discuss its fourth quarter and full year 2024 financial results and business highlights. The dial-in information for conference participants may be obtained by registering for the event. In addition, ARS Pharma Management will be participating in several upcoming

ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (("ARS Pharma", NASDAQ:SPRY). The agreement grants ALK exclusive global rights to the neffy® adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China. The deal delivers on key elements in ALK's new strategy Allergy+ and supports ALK's long-term financial ambitions. Needle-free, nasal delivery of adrenaline has the potential to become an important treatment option in anaphylaxisALK also gains rights to future indications, including acute urticaria flares (in development)ALK to pay USD 145 million in up

neffy Offers Adults and Children (≥30 kg) Living with Severe Allergic Reactions the First New Delivery Method for Epinephrine in more than 35 Years Well-capitalized to Support Launch and Commercialization of neffy in the U.S., and an Expected Operating Runway of at Least Three Years ARS Pharma to Host Investor Conference Call on Monday, August 12, 2024, at 8:00 am ET SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today announced that the U.S. Food and Drug Administration (FDA)

SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)